Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
To recruit volunteers more quickly for clinical trials, a team of National Institutes of Health (NIH) researchers has turned ...
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Medigene will slim its head count by 40% and pause plans to get its first asset into the clinic in order to channel cash to ...
Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...
A federal court jury has sided with Guardant Health, which had claimed that rival cancer test developer Natera went too far ...
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...
Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...
Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...